<SEC-DOCUMENT>0001193125-24-059461.txt : 20240306
<SEC-HEADER>0001193125-24-059461.hdr.sgml : 20240306
<ACCEPTANCE-DATETIME>20240305180825
ACCESSION NUMBER:		0001193125-24-059461
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240305
FILED AS OF DATE:		20240306
DATE AS OF CHANGE:		20240305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		24722999

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d787657d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as March 5, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d787657dex991.htm">Immutep Announces First Clinical Data from 90mg Dosing of Efti </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March 5, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d787657dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g787657g01g01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:4.00pt solid #6cb87e">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces First Clinical Data from 90mg Dosing of Efti </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Data from the safety <FONT STYLE="white-space:nowrap">lead-in</FONT> of the
<FONT STYLE="white-space:nowrap">AIPAC-003</FONT> trial shows 90mg efti in combination with paclitaxel is safe and well tolerated </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Encouraging initial efficacy in six metastatic breast cancer patients, who exhausted all endocrine therapy
including CDK4/6 inhibitors, demonstrated by a 50% overall response rate, including one complete response, and a 100% disease control rate </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; March 05, </B><B>2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;),
a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod
alpha (efti) in combination with weekly paclitaxel in patients from the safety <FONT STYLE="white-space:nowrap">lead-in</FONT> (N=6) of the <FONT STYLE="white-space:nowrap">AIPAC-003</FONT> Phase II/III trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Updated safety data from patients with <FONT STYLE="white-space:nowrap">HR-positive/HER2-negative/low</FONT> metastatic breast cancer (MBC) treated with this
innovative immuno-oncology (IO)-chemotherapy combination reveal no treatment-emergent serious adverse events. Additionally, all treatment-emergent adverse events during the safety observation period to date have been of mild severity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial efficacy reports show these six MBC patients, who exhausted all endocrine therapy including cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, exhibited
encouraging results achieving a 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate overall with the remaining three patients having stable disease as best response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acknowledging the early nature of these results, efti with paclitaxel historically has shown a dose-dependent effect in MBC and has in some cases also led to
stable disease patients becoming partial responders after six months. The biologically active 30mg efti dose, previously the highest dose of efti ever tested, has demonstrated a stronger immune response and greater efficacy than lower dosing levels
(1mg, 6mg) in multiple clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ongoing randomized Phase II portion of the trial, which will include up to 58 evaluable patients, is focused
on whether 90mg efti dosing is safe and more efficacious than 30mg dosing. This portion of the trial has enrolled 23 patients to date. Importantly, the determination of the optimal biological dose in <FONT STYLE="white-space:nowrap">AIPAC-003</FONT>
is directly tied to the&nbsp;<U>FDA&#146;s Project Optimus</U>&nbsp;initiative and is relevant for the entire efti program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further updates from <FONT
STYLE="white-space:nowrap">AIPAC-003</FONT> will be provided in CY2024. For more information on the trial, please visit clinicaltrials.gov (<U>NCT05747794</U>). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells,
CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT STYLE="white-space:nowrap">IFN-&#121;</FONT> and CXCL10 that further boost the immune system&#146;s ability to
fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer
(NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug
Administration (FDA). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g787657g01g01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:4.00pt solid #6cb87e">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g787657g01g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g787657g01g01.jpg
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MQ "[   " @,  P$             "08(!0<* @,$ 0$!  (# 0$!
M      4& P0' @@!$   !@$# @,% P@)!0     ! @,$!08' !$($@DA$Q0Q
M02(5%K8W=U%Q,B.U%Q@X84(DM#5U=G@Y\%-CMQD1  $# @0"!@4)! <)
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M'/M:TM)K RRQ,=+YA!<X D@ 4XUIQ6_RDTG1K[;C[JZM;>6\;<O87OC:]Q:
MUP!+@>&8C"@I14T[C&(:?BO,L,M1X=E7(>\T\)QS"Q2!&<8SFF4F[C7ZT>S1
M J#)%X@""ADTP*0%>HP '5J"W/90V=^TV[0UCV!U!@ 02*CJX#ATKG_-C0K#
M1->CDTV-L,-S!F+&#*T.:2TEH&#:C+6E,4T>T6!Y:NWC:;#(*G7?RW%.P.7R
MYS"8Z[O]VCU-PL<QA$3'663$PB/B(COKH&F2NFT^&5^+W1-)[Z"O^U?1VV;I
M][MVQNI3662UB+CUG(*GY2DI=CC^9'*'X(+?;:JZWE.)QW=%_D2S[_E50_\
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M2<'XZM&3+_-,86O5F*=OSG=N$D59)VB@H=E#1:1S H^EI5P4J+=!,#'44.
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M(F.+506SLG]H;D "+[RX9EVM<M%:8.H)I&3&<:;D:+9IIN$V<?4*W8L>SKF
M,W(U%,CY3Z1<)HID*+?95,#& .O8BPL;QO&LRD!)P=C-(?(<EP4]#MYE'RBU
M/&$(QMJ#'&=<.U374691;RXO%&ZBXE,=-1-)0W2W2'1%XV_$>2)%OF2FP*],
M&F9JGT)E]8962FF]EJ"$I7:U5[<S:UYK!O(VS*J,:YYT<H>0CP36<B58IR)
M*A%-K?AU*[7R<GIAV5*$E,=URLQJD<NX:V2OVNLW&7M</:XAX5(46;V&=O4%
MFBH&,8KA$0.0R8B!B*%PF%K_  V,<7QQK'6)3*&+;S.WI&359OXZH6I]/OKL
MWFV#U!%)V_@D)BOW9P!544G(L'I2'(1=(@D4(M@U2FW!UDB1RA>BUZ+>IT].
MBUJLUB3D)ULQBEY=.>FY68GY*$KJTA)2D@U;)HH)LDD6B#<1ZU3K&Z"+Z:EC
M^6KT)E.,<O&"R]YNUZLT8HW]3Y;1I:4$4F*#T5$2&]2W,F(J^6!R;#\(CHBU
MM3^-D)2C8"?P[&#93V,$D$K9)-UY<_SLHXRG*8]")(Y,HF .)J32<!YI$MD"
M&]AMBB1>^BXBL=,R1:[2>H8_DT[+D2T6E.YEN5F:VEC"61)!,&1JN-.6AG#Y
MFDD*(A\Q*F<@@8#%-X"18I7CK*)STI<6TT5W8 SHKE2/@92PVQSCZ3A'"42Q
M&,F:DHZ6K[.S1K9J=]'239@=9I+-VRW6<H*%$BRU_P"/TID^?R3+S^0)ZNM;
M15XJCU=A5F];7+$UZ+(,V$@^7L=5EGS:PK7AV=YUQ[AOLBR9_K!43ZBD6;>8
MCG+C9Z%9[],K(NX'%LS4[2E1K7<:E\UM,[)TZ0?NV;N >0;Y:M*&@'(E075
MY#*I_ (@)@(LIDS"\!;\5,,80,1!141#2=*6@V*R2[>-BXRMV&*=23-L9D4S
ME$9*LH/6!MO!PF[426$4U5=R+;$S'"\@96)9E10,\B7T<U*("F@B9PR5;(!T
MIE'H13$P>!0\"AX![M$23^"G:_S3Q:Y"P&7KM?L7V" BJQ:H->-JRUK/,*.9
EZ/3:-542RU>CF0H(J$$5.I4#;>P!]FB)Y&B(T1&B(T1&B+__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
